Clinical trial
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
NCT07621718 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
- Lead sponsor
- Revolution Medicines, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 22, 2026
- Completion date
- April 22, 2030
- Enrollment
- 670 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic adenocarcinoma, pancreatic adenocarcinoma metastatic, pancreatic adenosquamous carcinoma, pancreatic cancer, pancreatic cancer metastatic, pancreatic ductal adenocarcinoma (pdac), pdac, pdac - pancreatic ductal adenocarcinoma